$11.66 0.32 (+2.82%)
12/3/2009 4:00 PM

InterMune, Inc. (ITMN)

CAPS Rating: 2 out of 5

The Company is a biotech company focused on developing and commercializing innovative therapies in pulmonology and hepatology.

Featured Broker Partners